Characterization of the anti-HBV activity of HLP1-23, a human lactoferrin-derived peptide

Journal of Medical Virology

Volumn 85, Issue 5, 2013, Pages 780-788

  Florian, Paula E ^a   Macovei, Alina ^a   Lazar, Catalin ^a   Milac, Adina L ^a   Sokolowska, Izabela ^b   Darie, Costel C ^b   Evans, Robert W ^c   Roseanu, Anca ^a   Branza Nichita, Norica ^a  

^a INSTITUTE OF BIOCHEMISTRY OF THE ROMANIAN ACADEMY   (Romania)

^b CLARKSON UNIVERSITY   (United States)

^c BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

Antiviral; HepaRG; Infection; Lactoferrin; Virus binding

Indexed keywords

GLYCOSAMINOGLYCAN; HUMAN LACTOFERRIN DERIVED SYNTHETIC PEPTIDE 1 23; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEPATITIS B; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STATIC ELECTRICITY; VIRION;

ANTIVIRAL AGENTS; CELL LINE; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LACTOFERRIN; PEPTIDE FRAGMENTS; VIRUS INTERNALIZATION; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 84875642106     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23549     Document Type: Article

References (41)

1. Berlutti F, Pantanella F, Natalizi T, Frioni A, Paesano R, Polimeni A, Valenti P. 2011. Antiviral properties of lactoferrin-A natural immunity molecule. Molecules 16:6992-7018.
2. Darden T, York D, Pedersen L. 1993. Particle mesh Ewald: An N log(N) method for Ewald sums in large systems. J Chem Phys 98:10089-10093.
3. Farnaud S, Spiller C, Moriarty LC, Patel A, Gant V, Odell EW, Evans RW. 2004. Interactions of lactoferricin-derived peptides with LPS and antimicrobial activity. FEMS Microbiol Lett 233:193-199.
4. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. 1979. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 281:646-650.
5. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Trepo C, Guguen-Guillouzo C. 2002. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99:15655-15660.
6. Hanaoka K, Takasaki S, Kobata A, Miyamoto H, Nakamura T, Mayumi M. 1986. Structure of asparagine-linked sugar chains in the major polypeptide of hepatitis B surface antigen. J Biochem 99:1273-1276.
7. Hara K, Ikeda M, Saito S, Matsumoto S, Numata K, Kato N, Tanaka K, Sekihara H. 2002. Lactoferrin inhibits hepatitis B virus infection in cultured human hepatocytes. Hepatol Res 24:228.
8. Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA, Mattsby-Baltzer I. 2002. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol 220:83-95.
9. Humphrey W, Dalke A, Schulten K. 1996. VMD: Visual molecular dynamics. J Mol Graph 14:27-38.
10. Jiang R, Lonnerdal B. 2012. Apo- and holo-lactoferrin stimulate proliferation of mouse crypt cells but through different cellular signaling pathways. Int J Biochem Cell Biol 44:91-100.
11. Jiang R, Lopez V, Kelleher SL, Lonnerdal B. 2011. Apo- and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. J Cell Physiol 226:3022-3031.
12. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. 1983. Comparison of simple potential functions for simulating liquid water J Chem Phys 79:926-936.
13. Lazar C, Durantel D, Macovei A, Zitzmann N, Zoulim F, Dwek RA, Branza-Nichita N. 2007. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res 76:30-37.
14. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337:1733-1745.
15. Legrand D, Vigie K, Said EA, Elass E, Masson M, Slomianny MC, Carpentier M, Briand JP, Mazurier J, Hovanessian AG. 2004. Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells. Eur J Biochem 271:303-317.
16. Leistner CM, Gruen-Bernhard S, Glebe D. 2008. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 10:122-133.
17. Li S, Zhou H, Huang G, Liu N. 2009. Inhibition of HBV infection by bovine lactoferrin and iron-, zinc-saturated lactoferrin. Med Microbiol Immunol 198:19-25.
18. Macovei A, Radulescu C, Lazar C, Petrescu S, Durantel D, Dwek RA, Zitzmann N, Nichita NB. 2010. Hepatitis B virus requires intact caveolin-1 function for productive infection in HepaRG cells. J Virol 84:243-253.
19. Mann DM, Romm E, Migliorini M. 1994. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J Biol Chem 269:23661-23667.
20. Marchetti M, Longhi C, Conte MP, Pisani S, Valenti P, Seganti L. 1996. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res 29:221-231.
21. Marchetti M, Pisani S, Antonini G, Valenti P, Seganti L, Orsi N. 1998. Metal complexes of bovine lactoferrin inhibit in vitro replication of herpes simplex virus type 1 and 2. Biometals 11:89-94.
22. Milac AL, Buchete NV, Fritz TA, Hummer G, Tabak LA. 2007. Substrate-induced conformational changes and dynamics of UDP-N-acetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase-2. J Mol Biol 373:439-451.
23. Moriarty LC, Joannou CL, van den Berg JJ, Gorinsky B, Evans RW. 2004. Factors contributing to the potency of antimicrobial cationic peptides from the N-terminal region of human lactoferrin. FEMS Microbiol Lett 239:295-299.
24. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. 1999. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
25. Penco S, Scarfi S, Giovine M, Damonte G, Millo E, Villaggio B, Passalacqua M, Pozzolini M, Garre C, Benatti U. 2001. Identification of an import signal for, and the nuclear localization of, human lactoferrin. Biotechnol Appl Biochem 34:151-159.
26. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, Schulten K. 2005. Scalable molecular dynamics with NAMD. J Comput Chem 26:1781-1802.
27. Robinson WS. 1977. The genome of hepatitis B virus. Annu Rev Microbiol 31:357-377.
28. Robinson WS, Clayton DA, Greenman RL. 1974. DNA of a human hepatitis B virus candidate. J Virol 14:384-391.
29. Schmitt S, Glebe D, Tolle TK, Lochnit G, Linder D, Geyer R, Gerlich WH. 2004. Structure of pre-S2 N- and O-linked glycans in surface proteins from different genotypes of hepatitis B virus. J Gen Virol 85:2045-2053.
30. Schulze A, Gripon P, Urban S. 2007. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46:1759-1768.
31. Schulze A, Mills K, Weiss TS, Urban S. 2011. Hepatocyte polarization is essential for the productive entry of the hepatitis B virus. Hepatology 55:373-383.
32. Sells MA, Chen ML, Acs G. 1987. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci USA 84:1005-1009.
33. Siciliano R, Rega B, Marchetti M, Seganti L, Antonini G, Valenti P. 1999. Bovine lactoferrin peptidic fragments involved in inhibition of herpes simplex virus type 1 infection. Biochem Biophys Res Commun 264:19-23.
34. Sokolowska I, Woods AG, Gawinowicz MA, Roy U, Darie CC. 2012. Identification of potential tumor differentiation factor (TDF) receptor from steroid-responsive and steroid-resistant breast cancer cells. J Biol Chem 287:1719-1733.
35. Son KN, Park J, Chung CK, Chung DK, Yu DY, Lee KK, Kim J. 2002. Human lactoferrin activates transcription of IL-1beta gene in mammalian cells. Biochem Biophys Res Commun 290:236-241.
36. Summers J, O'Connell A, Millman I. 1975. Genome of hepatitis B virus: Restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci USA 72:4597-4601.
37. Superti F, Ammendolia MG, Valenti P, Seganti L. 1997. Antirotaviral activity of milk proteins: Lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med Microbiol Immunol 186:83-91.
38. Thomassen EA, van Veen HA, van Berkel PH, Nuijens JH, Abrahams JP. 2005. The protein structure of recombinant human lactoferrin produced in the milk of transgenic cows closely matches the structure of human milk-derived lactoferrin. Transgenic Res 14:397-405.
39. Tomita M, Takase M, Bellamy W, Shimamura S. 1994. A review: The active peptide of lactoferrin. Acta Paediatr Jpn 36:585-591.
40. Treichel U, Meyer zum Buschenfelde KH, Dienes HP, Gerken G. 1997. Receptor-mediated entry of hepatitis B virus particles into liver cells. Arch Virol 142:493-498.
41. Valenti P, Antonini G. 2005. Lactoferrin: An important host defence against microbial and viral attack. Cell Mol Life Sci 62:2576-2587.